Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 29, 2009 Brian Orelli	Merck's Bad News Nothing to Sneeze At The U.S. Patent and Trademark Office reexamination of Merck's patent on allergy medication, Singulair, is nothing to sneeze at. The $2.8 billion worth of Singulair that Merck sold in the U.S. last year made up 12% of its total pharmaceutical sales.
The Motley Fool January 31, 2005 Stephen D. Simpson	Merck Takes Another Body Blow Loss of exclusivity on major osteoporosis drug could take steam out of the recovery process. Investors in Merck just can't catch a break.
Chemistry World June 20, 2012	Nasonex patent ruling goes against Merck & Co The US court ruled that, although the Merck patent in question was valid, it should not stop Canadian generics company Apotex marketing its mometasone furoate product.
IndustryWeek December 1, 2008 Jill Jusko	Litigation Nation: By the Numbers Patent infringement claims bedevil manufacturers, survey finds.
The Motley Fool February 26, 2010 Brian Orelli	Boning Up on Pfizer's Drug Fablyn looks OK on paper, but that isn't going to cut it in the crowded osteoporosis market.
The Motley Fool March 31, 2010 Brian Orelli	When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies.
The Motley Fool August 30, 2010 Brian Orelli	Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help.
The Motley Fool January 8, 2010 Brian Orelli	Heartburn Relieved ... for Now AstraZeneca settles its patent dispute with Teva.
The Motley Fool February 28, 2008 Brian Lawler	Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year.
Bio-IT World November 2005 Patrick R. Scanlon	Patent Term Extension Primer U.S. patent law includes provisions for extending the patent term of medical devices and pharmaceuticals in instances when lengthy FDA approval is taking place during the term.
Chemistry World May 8, 2015 Matthew Gunther	Court rejects Spain's challenge to EU patent reform The European Court of Justice has dismissed a legal challenge by Spain to block the introduction of a single patent system in Europe.
The Motley Fool February 11, 2010 Brian Orelli	A Turnaround Year, But Not in a Good Way 2009 was a solid year for sanofi-aventis thanks to a boost from sales of swine flu vaccine and some help from the exchange rate. But 2010? Not so solid.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool February 29, 2008 Brian Orelli	Barred by Debt The picture continues to look bleak at Barr Labs, due to debt taken on to acquire Pliva in 2006.
The Motley Fool March 11, 2010 Brian Orelli	FDA Still Has a Bone to Pick With These Drugmakers Osteoporosis drugs remain under the microscope.
The Motley Fool January 31, 2007 Brian Lawler	Merck Plays the Waiting Game New acquisitions may help the drugmaker weather tough times. Investors, take note.
The Motley Fool February 15, 2005 Stephen D. Simpson	Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma.
Chemistry World June 14, 2013 Phillip Broadwith	Pfizer and Takeda win $2.15bn in patent payout Pfizer and Takeda will share a $2.15 billion settlement after suing generic drugmakers Teva and Sun Pharmaceuticals for patent infringement.
The Motley Fool March 3, 2010 Brian Orelli	Judge's Ruling Has Brand and Generic Drugmakers Smiling A ruling on the patents on Merck's blood pressure medications Cozaar and Hyzaar benefited both Merck and the plaintiff in the suit, generic-drug maker Teva Pharmaceuticals. The defendant in the suit wasn't actually Merck but the Food and Drug Administration.
PC Magazine August 17, 2004 Sebastian Rupley	I, Server Would your body make a good network server? The U.S. Patent Office took the idea seriously enough to award Microsoft a patent.
The Motley Fool March 15, 2005 Stephen D. Simpson	IVAX Is No Placebo The maker of generic drugs moves higher on fourth-quarter results that surprised Wall Street.
The Motley Fool July 27, 2010 Brian Orelli	Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts.
The Motley Fool October 22, 2008 Brian Orelli	Merck's a Bloated Garbage Heap of Stale Drugs Now Merck is planning on cutting 12% of its workforce in the hopes of saving $4 billion through 2013.
The Motley Fool June 26, 2006 Stephen D. Simpson	Is Novartis the Future of Generics? Merck's recent pricing action might just be the beginning of the end of generics as we know them. Investors, take note.
The Motley Fool June 3, 2010 Brian Orelli	When All Else Fails, Sue Your Competitors Biogen thinks its patent covers its competitors' drugs in addition to Avonex and has filed a lawsuit demanding royalties from its competitors.
The Motley Fool April 22, 2008 Brian Orelli	Will Merck Make It? Merck releases first-quarter results and says it can meet its previous guidance.
The Motley Fool January 25, 2010 Brian Orelli	Pay-for-Delay Is Under the Spotlight It helps each side, but governments aren't thrilled with the idea.
IndustryWeek August 1, 2006	Patents: Eleven Issues To Consider... How patent savvy are you?
The Motley Fool January 21, 2011 Brian Orelli	Mark Your Calendar, Drug Investors Vertex announces that the Food and Drug Administration has accepted its New Drug Application to market telaprevir.
Pharmaceutical Executive October 1, 2010	Euro Soul-Searching on Competition A report by the European Commission aimed at exploring patent exploitation by Big Pharma winds up generating more angst than answers.
The Motley Fool March 13, 2008 Stephen Albainy-Jenei	Pfizer's Celebrex Aches and Pains The Court of Appeals for the Federal Circuit upholds a lower court's ruling that found Teva Pharmaceutical had infringed two of Pfizer's patents for Celebrex.
The Motley Fool January 25, 2011 Brian Orelli	2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform.
The Motley Fool July 30, 2010 Brian Orelli	On the Path to a Blockbuster Amgen's Prolia will be a blockbuster. Eventually.
The Motley Fool August 13, 2010 Brian Orelli	Already a Slippery Slope for Eli Lilly The company gets a whiff of what its patent cliff might be like.
The Motley Fool December 21, 2006 Brian Lawler	Dueling Fools: Merck Bull Rebuttal Plenty of cash. Big pipeline. Not to worry. The future can't be predicted, but Merck's history shows its ability to weather even the toughest pharmaceutical-development environments.
The Motley Fool May 12, 2010 Brian Orelli	Is Merck a Buy? Short term it's hard to say, but for the long term, its pipeline looks strong.
Home Theater June 11, 2010 Mark Fleischmann	TiVo Patent Claim Rejected Federal patent agency says company doesn't own DVR concept.
The Motley Fool September 25, 2006 Brian Lawler	Merck's Positive Contribution Bad press from Vioxx shouldn't overshadow the company's new offering. Investors, take note.
Bank Technology News July 2008 Glen Fest	IP Practices Core to Patent Strategy John Cronin, managing director of ipCapital Group, but best known as the founder of IBM's "Patent Factory," says banks themselves are to blame for their patent predicament.
IEEE Spectrum December 2007 Kirk Teska	The Foreign Patent Money Trap You may well need patents in many countries, but that doesn't mean you can afford them.
InternetNews September 3, 2009	Microsoft: Can't Our Patent Systems Get Along? Senior Microsoft legal eagle advocates "harmonization" of patent systems worldwide in blog post.
Chemistry World August 23, 2012 Dean Baker	Monopoly money It is remarkable that the system of patent support for prescription drug research has not become more of a policy issue.
The Motley Fool May 16, 2007 Rich Duprey	Mylan's Costly Bid to Capture the Flag Its winning bid for a German Merck unit might be why it's falling behind in the generics game. Investors, take note.
The Motley Fool September 20, 2007 Billy Fisher	More Options for Healthy Bones? Novartis and Wyeth might be able to offer alternative treatments for osteoporosis, but the companies have a tough road ahead in this market.
The Motley Fool October 14, 2010 Sean Williams	Should You Let AstraZeneca Go? Multiple drug patent expirations await. It's time to run away.
The Motley Fool May 28, 2008 Brian Orelli	A Rough Quarter for Generic-Drug Makers Investors rocked the smaller companies the most.
BusinessWeek June 24, 2010 Bliss & Decker	Ending the Silence of Generic Drugmakers The FTC says drugmakers are paying generic rivals not to compete.
The Motley Fool January 28, 2008 Brian Lawler	A Wing and a Prayer for Amgen Amgen announces data from its top pipeline drug candidate. Investors, take note.